PCSK9 rs11597132: What Your Genotype Means
The rs11597132 single nucleotide polymorphism, commonly known as the R46L variant, is a missense alteration located in the PCSK9 gene. This genetic change is classified as a loss-of-function variant that leads to decreased levels of low-density lipoprotein (LDL) cholesterol in circulation. Epidemiological and genetic studies consistently link this alteration to a lifelong reduction in the risk of coronary heart disease.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | This common genotype reflects two standard functional alleles of the PCSK9 gene, representing the biological baseline seen in most individuals worldwide. People with this genotype have standard PCSK9 enzyme activity and normal rates of LDL receptor recycling. It is associated with average population levels of circulating LDL cholesterol and standard cardiovascular baseline risk. | Informational |
| GA | Carrying one copy of the minor A allele confers a partial loss of PCSK9 enzyme function, leading to increased LDL receptor recycling on liver cells. Observational studies demonstrate that individuals with this genotype typically maintain lifetime LDL cholesterol levels that are approximately 10% to 15% lower than non-carriers. This reduction in circulating atherogenic particles correlates statistically with a reduced risk of coronary heart disease. | Favorable |
| AA | This rare homozygous genotype occurs when an individual inherits two copies of the loss-of-function variant, significantly suppressing PCSK9 activity. In human cohorts, this genotype is exceptionally infrequent but is associated with substantially reduced plasma LDL cholesterol levels due to enhanced hepatic clearance. Carriers of this genotype display an even stronger statistical protection against premature coronary artery disease. | Favorable |
Genomic Location and the R46L Variant
The single nucleotide polymorphism rs11597132 is situated on chromosome 1 within exon 1 of the PCSK9 (proprotein convertase subtilisin/kexin type 9) gene. At the molecular level, this variant involves a nucleotide transition from a guanine (G) to an adenine (A) on the forward genomic strand. This single-base substitution replaces the amino acid arginine with leucine at codon 46 of the resulting polypeptide, earning it the designation PCSK9 R46L in scientific literature. The minor A allele (often represented as T in complementary strand notations) impairs the normal maturation, stability, or secretion of the encoded proprotein convertase. Because this missense change reduces the active output of the functional enzyme rather than amplifying it, genomic repositories and functional assays classify rs11597132 as a classical loss-of-function variant. Although loss-of-function changes are frequently disruptive in metabolic pathways, partial suppression of PCSK9 is biologically advantageous for hepatic lipid clearance.
Biological Role of the PCSK9 Gene
The PCSK9 gene provides instructions for producing an enzyme predominantly secreted by hepatocytes into the circulatory system. In normal physiology, circulating PCSK9 binds directly to the low-density lipoprotein receptor (LDLR) on the surface of liver cells. When the LDLR-PCSK9 complex is internalized into the cell, PCSK9 prevents the receptor from recycling back to the cell surface, instead directing it into lysosomes where it is degraded. By eliminating LDLRs, PCSK9 inherently restricts the liver's capacity to clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream. Individuals who harbor genetic variants that decrease functional PCSK9 activity exhibit greater numbers of recycled LDL receptors on their hepatocytes. This higher receptor abundance accelerates the uptake of circulating LDL particles, thereby driving down baseline plasma cholesterol concentrations over an individual's entire lifetime without impairing fundamental liver physiology.
Cardiovascular Associations and Research Strength
Multiple prospective cohort studies and genome-wide association investigations have examined the metabolic impact of rs11597132. Heterozygous carriers of the minor allele typically exhibit an average reduction of 10% to 15% in circulating LDL-C levels compared to non-carriers. Because this reduction is present from birth, observational studies such as those highlighted in primary biomedical literature demonstrate that long-term cardiovascular benefits are disproportionately large, showing a meaningful decrease in lifetime coronary heart disease incidence. Functional characterizations suggest carriers also display lower concentrations of very-low-density lipoproteins and apolipoprotein B-containing particles. However, catalog evidence strength for this specific single variant remains categorially limited when compared to rare, highly penetrant familial mutations. Furthermore, observational meta-analyses indicate that while coronary heart disease risks are diminished, rs11597132 is not consistently associated with a reduction in ischemic stroke risk, illustrating phenotypic specificity.
Ancestry and Population Distribution
The distribution of the rs11597132 minor allele shows substantial geographic and ancestral variation across global populations cataloged in repositories such as gnomAD. In individuals of European ancestry, the minor allele frequency typically ranges between 1% and 3%, meaning that approximately 2% to 6% of people in these populations carry at least one copy of the protective variant. In contrast, the variant is exceptionally rare or practically absent in populations of East Asian, African, and Indigenous American ancestries. In African descent cohorts, other distinct PCSK9 loss-of-function mutations, such as Y142X and C679X, are far more common and account for similar biological reductions in LDL-C. Because rs11597132 is largely restricted to European ancestries, polygenic risk interpretations and clinical trial generalizations must be carefully contextualized, as absence of this allele does not imply an inherently elevated baseline risk in non-European groups.
Navigating Results and Clinical Boundaries
Discovering an rs11597132 genotype provides educational insight into one element of personal metabolic biology, but it cannot be used as an independent clinical diagnosis. Carrying a protective allele does not confer absolute immunity from atherosclerosis or heart disease; lifestyle factors, smoking status, hypertension, diet, and secondary lipids play major roles in cardiovascular outcomes. Conversely, having two copies of the common non-protective allele is the standard baseline state for the vast majority of people worldwide and does not signify an inherited disorder. Genetic insights regarding PCSK9 inspired the modern development of therapeutic PCSK9 inhibitors and lipid-lowering monoclonal antibodies. However, commercial direct-to-consumer testing results must never be used to initiate, alter, or discontinue prescription medications such as statins. Any cardiovascular risk assessments or therapeutic dosing adjustments must be coordinated directly with a licensed physician or clinical pharmacist.
How common is this variant?
The minor allele frequency for rs11597132 is approximately 1% to 3% in populations of European ancestry, whereas it is extremely rare or virtually absent in African, East Asian, and other non-European populations.
Frequently asked questions
What is the PCSK9 R46L variant?
The PCSK9 R46L variant, indexed as rs11597132, is a naturally occurring DNA sequence change in the PCSK9 gene. It substitutes the amino acid arginine with leucine at position 46, which slightly impairs the function of the PCSK9 enzyme. This loss of function leads to more LDL receptors on liver cells and lower circulating cholesterol.
Does carrying the rs11597132 variant guarantee I will never get heart disease?
No, carrying the variant does not guarantee freedom from heart disease. While having the allele is associated with lower average lifetime LDL cholesterol and reduced statistical risk, cardiovascular disease is complex and multifactorial. Factors such as diet, physical activity, blood pressure, blood glucose, and other genetic variants still heavily influence overall risk.
How does rs11597132 relate to PCSK9 inhibitor medications?
The discovery of natural loss-of-function variants like rs11597132 proved to researchers that reducing PCSK9 activity safely lowers cholesterol without toxic side effects. This genetic finding directly spurred pharmaceutical companies to develop PCSK9-inhibiting drugs that mimic the natural protective effect seen in carriers of the variant.
Should I stop taking my cholesterol medication if I have the protective allele?
No, you should never modify or stop taking prescribed cardiovascular medications based on a direct-to-consumer genetic test. Genetic markers provide only statistical associations and do not reflect your real-time lipid profile or total arterial health. Any changes to statins or other therapies must be discussed with your physician.
Why is this variant rarely found in non-European populations?
The rs11597132 mutation arose historically after modern human ancestral groups migrated into Eurasia, leading to a founder distribution primarily seen in individuals of European heritage. Other populations possess different unique loss-of-function variants in the PCSK9 gene, such as Y142X in people of African ancestry, that provide similar cholesterol-lowering effects.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11597132?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29